These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19839977)

  • 21. Omalizumab: a review of its use in the management of allergic asthma.
    Bang LM; Plosker GL
    Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
    Lowe PJ; Renard D
    Br J Clin Pharmacol; 2011 Aug; 72(2):306-20. PubMed ID: 21392073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omalizumab.
    Easthope S; Jarvis B
    Drugs; 2001; 61(2):253-60; discussion 261. PubMed ID: 11270941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma.
    Chung KF
    Expert Opin Pharmacother; 2004 Feb; 5(2):439-46. PubMed ID: 14996639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of humanized Anti-IgE antibodies (omalizumab). A new principle in the treatment of allergic diseases in ENT medicine].
    Pfaar O; Klimek L
    HNO; 2007 Dec; 55(12):981-90; quiz 991-2. PubMed ID: 17992493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
    D'Amato G; Salzillo A; Piccolo A; D'Amato M; Liccardi G
    Ther Clin Risk Manag; 2007 Aug; 3(4):613-9. PubMed ID: 18472983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
    Kupryś-Lipińska I; Molińska K; Kuna P
    Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti-IgE therapy in persistent allergic asthma].
    Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
    Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of omalizumab in asthma.
    Price D
    Prim Care Respir J; 2008 Jun; 17(2):62-72. PubMed ID: 18425299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI.
    Maggi L; Rossettini B; Montaini G; Matucci A; Vultaggio A; Mazzoni A; Palterer B; Parronchi P; Maggi E; Liotta F; Annunziato F; Cosmi L
    Eur J Immunol; 2018 Dec; 48(12):2005-2014. PubMed ID: 30252930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.
    Bush RK
    Treat Respir Med; 2004; 3(1):45-57. PubMed ID: 15174893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-IgE monoclonal antibody for the treatment of the asthma and other manifestations related to allergic diseases.
    Sarinho E; Cruz AA
    J Pediatr (Rio J); 2006 Nov; 82(5 Suppl):S127-32. PubMed ID: 17136288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
    Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
    Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omalizumab: a review of its use in the treatment of allergic asthma.
    Plosker GL; Keam SJ
    BioDrugs; 2008; 22(3):189-204. PubMed ID: 18481901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting immunoglobulin E as a novel treatment for asthma.
    Sandström T
    Curr Allergy Asthma Rep; 2005 Mar; 5(2):109-15. PubMed ID: 15683610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of action of anti-immunoglobulin E therapy.
    Soresi S; Togias A
    Allergy Asthma Proc; 2006; 27(2 Suppl 1):S15-23. PubMed ID: 16722327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab in asthma: an update on recent developments.
    Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
    J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.